Renal pathology in Fabry disease
Renal pathology in Fabry disease
复制标题
DOI:
10.1097/01.asn.0000016684.07368.75
复制
发表时间:
2002-06-01
影响因子:
13.6
通讯作者:
Kopp, JB
中科院分区:
文献类型:
--
作者:
Alroy, J;Sabnis, S;Kopp, JB
Fabry disease is an X-linked recessive lysosomal storage disease that is caused by deficient activity of the lysosomal enzyme α-galactosidase A (α-Gal A), an enzyme that cleaves terminal α-galactosyl residues. This deficiency results in progressive lysosomal accumulation of glycosphingolipid with terminal α-galactosyl residues, particularly globotriaosylceramide (Gb3). Gb3 accumulates in many cells, particularly in renal epithelial cells, endothelial cells, pericytes, vascular smooth muscle cells, cardiomyocytes, and neurons of the autonomic nervous system (1).The genetic defect occurs in all cell types, but involvement differs greatly among different organs and cell types. This heterogeneity likely reflects different rates of sphingolipid metabolism. Thus the minimum threshold requirement for α-Gal A activity to prevent Gb3 accumulation varies across cell types due to the type and amount of substrates that are recycled by the different cells (2). Renal lesions are found in both hemizygous (male) and heterozygous (female) patients. Renal symptoms in the latter are typically milder and delayed by 2 to 3 decades, but there is considerable variability (3). The variability is likely the result of the random nature of X inactivation, resulting in considerable variability in α-Gal A activity among carriers and (at least theoretically) within one carrier individual among various tissues or regions of a single tissue.